This business information is not released now.

This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.

R-Tech Ueno, Ltd.
Pharmaceutical/Drug Discovery

last update:2015/2/23

Delegates :
Yukihiko Mashima

Incorporated :
September  21 , 1989

Paid in Capital :
658670 Million yen  

Employees :
77 人

Address :
NBF Hibiya Building 1-1-7 Uchisaiwaicho, Chiyoda-ku TOKYO

+81-3-3596-8011 / +81-3-3596-8023


Attachment :

Mission/Background :
R-Tech Ueno is a drug discovery venture company established in September 1989 for the purpose of R&D and marketing of drugs. Under the leadership of the CEO, also a medical doctor, the company is developing new drugs on the theme “Physician-Oriented New Drug Innovation”, targeting ophthalmologic and dermatologic diseases that previously had no effective therapeutic agent.
We aim to become a “global pharmaceutical company specializing in specific fields (ophthalmology and dermatology) and developing and selling pharmaceutical products through the eyes of doctors.” We are promoting the development of new drugs for unmet medical needs for which the government provides recommendations and assistance such as orphan drugs and the drugs in the field of anti-aging (lifestyle drugs).

Technology & Business
1) Research and Development of new drugs (Drug Discovery): Drug discovery business, where new drugs are developed to become future sources of earnings. Centering on Dr. Mashima, the President of R-Tech Ueno, and a physician as an ophthalmological specialist, we are promoting development of new drugs focusing on the three targets, these are drugs for unmet medical needs encouraged by the government, drugs for orphan diseases (orphan drugs), and life-style improving drugs (anti-aging drugs).
2) Manufacturing and Marketing of drugs: The manufacture and sale of Rescula® Eye Drops, with sales promoted through nationwide hospitals and dispensing pharmacies.
3) Development support and Contact Manufacturing Services: R-Tech Ueno manufactures AMITIZA® Capsules developed by Sucampo Pharmaceutical, Inc. of the United States on a consigned basis, and we provide research and development support services to other companies.
Products & Service
Products & Service Name
Japan to the world's first unoprostone 0.15% eye drops as retinitis pigmentosa treatment
Completion of Phase 3
Severe dry eye recombinant human serum albumin
Inflammatory disease treatment of new mechanism of action based on the VAP-1 inhibitory effect
Completion of Phase 1
Male pattern baldness and eyelashes hypotrichosis disease treatment

We have started the phase 1 clinical trial for the new molecular entity RTU-1096, which is a VAP-1inhibitor having anti-inflammatory and immunomodulatory effects. Orphan Drug Designation for Unoprostone Isopropyl (development code: UF-021) for the treatment of retinitis pigmentosa from MHLW. The completion of a Phase I/II clinical study of recombinant human serum albumin-containing ophthalmic solution (development code: RU-101) for the treatment of severe dry eye.
Hot news
Nov.25, 2014:Orphan Drug Designation for Unoprostone
Nov.10, 2014: Completion of a Phase I/II of rHSA eye drop in the US for severe dry eye
Oct. 20,2014: Initiation of the Phase I for the novel VAP-1 Inhibitor RTU-1096

Alliance strategy
RU-101, we hope the derivation of the pipeline of RTU-1096 and RK-023.

This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.